RxDoctor Payments DataLook up a doctor →

John Eatman, MD

Neurology · North Kansas City, MONPI 1942596523

Payments from drug & device makers

$83,853in general payments, 2019–2025

Across 477 payments — averaging $175.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$39K
  • Alnylam Pharmaceuticals Inc.$34K
  • Amgen$3K
  • AbbVie$2K
  • Argenx US, Inc.$1K
  • Akcea Therapeutics, Inc.$1K
  • plus $4K from 37 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)48$38,546
Alnylam Pharmaceuticals Inc.44$34,414
Amgen(2 entities)6$2,568
AbbVie138$1,655
Argenx US, Inc.14$1,444
Akcea Therapeutics, Inc.3$1,077
MDD US Operations, LLC4$423
Acadia Pharmaceuticals Inc21$398
Pfizer47$397
Biogen16$348
Amneal Pharmaceuticals LLC12$322
Lilly USA, LLC11$198
UCB, Inc.13$198
Bristol Myers Squibb25$195
EMD Serono, Inc.4$193
Genentech USA, Inc.8$162
Lundbeck LLC6$151
Kyowa Kirin, Inc.6$110
Otsuka America Pharmaceutical, Inc.5$87
Ultragenyx Pharmaceutical Inc.5$83
Catalyst Pharmaceuticals, Inc.3$77
Upsher-smith Laboratories LLC1$69
Takeda Pharmaceuticals U.S.A., Inc.2$59
Boston Scientific2$58
Corium, LLC3$56
Hospira, Inc.3$47
Novartis3$47
Jazz Pharmaceuticals Inc.2$40
Impel Pharmaceuticals Inc.2$40
Abbott2$40
Teva Pharmaceuticals USA, Inc.2$40
SK Life Science, Inc.2$38
Axsome Therapeutics, Inc.2$36
Octapharma USA, Inc.2$35
Neurelis, Inc.1$31
Sumitomo Pharma America, Inc.2$29
Sanofi1$26
Eisai Inc.1$26
Averitas Pharma Inc.1$25
Merz Pharmaceuticals, LLC1$21
Mallinckrodt Hospital Products Inc.1$18
Grifols USA, LLC1$14
Neurocrine Biosciences, Inc.1$12

How this compares

$83,853 in reported general payments places this provider in the 80th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri →

Medicare billing

Part B allowed, 2024
$101,850
Medicare patients
291
Services billed
2,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in North Kansas City

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →